192 related articles for article (PubMed ID: 22809877)
1. Metabolomic biomarkers in women with polycystic ovary syndrome: a pilot study.
Atiomo W; Daykin CA
Mol Hum Reprod; 2012 Nov; 18(11):546-53. PubMed ID: 22809877
[TBL] [Abstract][Full Text] [Related]
2. Metabonomics reveals plasma metabolic changes and inflammatory marker in polycystic ovary syndrome patients.
Sun L; Hu W; Liu Q; Hao Q; Sun B; Zhang Q; Mao S; Qiao J; Yan X
J Proteome Res; 2012 May; 11(5):2937-46. PubMed ID: 22428626
[TBL] [Abstract][Full Text] [Related]
3. Tryptophan 64 --> arginine polymorphism of beta-3-adrenergic receptor in Chilean women with polycystic ovary syndrome.
Pérez-Bravo F; Echiburú B; Maliqueo M; Santos JL; Sir-Petermann T
Clin Endocrinol (Oxf); 2005 Feb; 62(2):126-31. PubMed ID: 15670186
[TBL] [Abstract][Full Text] [Related]
4. Identification of potential metabolic biomarkers of polycystic ovary syndrome in follicular fluid by SWATH mass spectrometry.
Sun Z; Chang HM; Wang A; Song J; Zhang X; Guo J; Leung PCK; Lian F
Reprod Biol Endocrinol; 2019 Jun; 17(1):45. PubMed ID: 31186025
[TBL] [Abstract][Full Text] [Related]
5. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
Barber TM; Wass JA; McCarthy MI; Franks S
Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
[TBL] [Abstract][Full Text] [Related]
6. Serum metabolomics of Indian women with polycystic ovary syndrome using
RoyChoudhury S; Mishra BP; Khan T; Chattopadhayay R; Lodh I; Datta Ray C; Bose G; Sarkar HS; Srivastava S; Joshi MV; Chakravarty B; Chaudhury K
Mol Biosyst; 2016 Oct; 12(11):3407-3416. PubMed ID: 27714060
[TBL] [Abstract][Full Text] [Related]
7. Effects of menstrual cycle phase on metabolomic profiles in premenopausal women.
Wallace M; Hashim YZ; Wingfield M; Culliton M; McAuliffe F; Gibney MJ; Brennan L
Hum Reprod; 2010 Apr; 25(4):949-56. PubMed ID: 20150174
[TBL] [Abstract][Full Text] [Related]
8. Serum resistin and adiponectin levels in young non-obese women with polycystic ovary syndrome.
Arikan S; Bahceci M; Tuzcu A; Kale E; Gökalp D
Gynecol Endocrinol; 2010 Mar; 26(3):161-6. PubMed ID: 20148738
[TBL] [Abstract][Full Text] [Related]
9. Metabolomic analysis of the plasma of patients with high-altitude pulmonary edema (HAPE) using 1H NMR.
Luo Y; Zhu J; Gao Y
Mol Biosyst; 2012 Jun; 8(6):1783-8. PubMed ID: 22498880
[TBL] [Abstract][Full Text] [Related]
10. Increased acylation-stimulating protein, C-reactive protein, and lipid levels in young women with polycystic ovary syndrome.
Wu Y; Zhang J; Wen Y; Wang H; Zhang M; Cianflone K
Fertil Steril; 2009 Jan; 91(1):213-9. PubMed ID: 18206145
[TBL] [Abstract][Full Text] [Related]
11. Insulin response to oral glucose in healthy, lean young women and patients with polycystic ovary syndrome.
Kulshreshtha B; Ganie MA; Praveen EP; Gupta N; Lal Khurana M; Seith A; Dwivedi SN; Kumar G; Ammini AC
Gynecol Endocrinol; 2008 Nov; 24(11):637-43. PubMed ID: 19031221
[TBL] [Abstract][Full Text] [Related]
12. Obesity, body composition and metabolic disturbances in polycystic ovary syndrome.
Svendsen PF; Nilas L; Nørgaard K; Jensen JE; Madsbad S
Hum Reprod; 2008 Sep; 23(9):2113-21. PubMed ID: 18556679
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of the metabolic syndrome in German women with polycystic ovary syndrome.
Hahn S; Tan S; Sack S; Kimmig R; Quadbeck B; Mann K; Janssen OE
Exp Clin Endocrinol Diabetes; 2007 Feb; 115(2):130-5. PubMed ID: 17318774
[TBL] [Abstract][Full Text] [Related]
14. Metabolomic investigation of Arthus reaction in a rat model using proton nuclear magnetic resonance (1H NMR) spectroscopy and rapid resolution liquid chromatography (RRLC).
Zhang X; Shen J; Cao B; Xu L; Zhao T; Liu X; Zhang H
Mol Biosyst; 2013 Jun; 9(6):1423-35. PubMed ID: 23511749
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of the phosphoprotein enriched in diabetes gene product (Ped/pea-15) in women with polycystic ovary syndrome.
Savastano S; Orio F; Palomba S; Cascella T; Manguso F; Lupoli GA; Formisano P; Lombardi G; Colao A; Beguinot F; Valentino R
Clin Endocrinol (Oxf); 2007 Oct; 67(4):557-62. PubMed ID: 17590172
[TBL] [Abstract][Full Text] [Related]
16. Association of polycystic ovary syndrome with cardiovascular risk factors.
Akram T; Hasan S; Imran M; Karim A; Arslan M
Gynecol Endocrinol; 2010 Jan; 26(1):47-53. PubMed ID: 19639500
[TBL] [Abstract][Full Text] [Related]
17. Metabolomic biomarkers of impaired glucose tolerance and type 2 diabetes mellitus with a potential for risk stratification in women with polycystic ovary syndrome.
Galazis N; Iacovou C; Haoula Z; Atiomo W
Eur J Obstet Gynecol Reprod Biol; 2012 Feb; 160(2):121-30. PubMed ID: 22136882
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of the metabolic syndrome in women with a previous diagnosis of polycystic ovary syndrome: long-term follow-up.
Hudecova M; Holte J; Olovsson M; Larsson A; Berne C; Sundstrom-Poromaa I
Fertil Steril; 2011 Nov; 96(5):1271-4. PubMed ID: 21872228
[TBL] [Abstract][Full Text] [Related]
19. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome.
Diamanti-Kandarakis E; Katsikis I; Piperi C; Alexandraki K; Panidis D
Clin Endocrinol (Oxf); 2007 Jan; 66(1):103-9. PubMed ID: 17201808
[TBL] [Abstract][Full Text] [Related]
20. Alterations in the levels of plasma amino acids in polycystic ovary syndrome--A pilot study.
Unni SN; Lakshman LR; Vaidyanathan K; Subhakumari KN; Menon NL
Indian J Med Res; 2015 Nov; 142(5):549-54. PubMed ID: 26658589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
